Arthritis program

Design, synthesis, pre-clinical testing manufacturing scale-up of the novel lead compounds will be accomplished working closely with a Canadian CRO specializing in drug discovery.
Working iteratively, GenBio Inc will employ molecular modelling and other rational approaches to discover and optimize lead drug candidates based on our core scaffold, while maintain cost effective strategies to scale up the manufacturing process for commercial feasibility.
All intellectual property will be exclusively owned by GenBio Inc and licensed accordingly
There is significant market demand for a low side effect, novel class of COX-2 inhibitor drugs, and that the development of such is likely to trigger competing large bids from the numerous international pharmaceutical companies eager to own a patented compound in this currently unoccupied multi-billion-dollar market segment.